Parenteral Pharma Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
as on 25-06-2024
- Paid Up Capital ₹ 0.96 M
as on 25-06-2024
- Company Age 20 Year, 8 Months
- Last Filing with ROC 31 Mar 2020
- Open Charges ₹ 2.13 Cr
as on 25-06-2024
- Revenue %
(FY 2020)
- Profit -60323.58%
(FY 2020)
- Ebitda -118239.08%
(FY 2020)
- Net Worth -716.03%
(FY 2020)
- Total Assets -75.68%
(FY 2020)
About Parenteral Pharma
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2020. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 0.96 M.
The company currently has active open charges totaling ₹2.13 Cr.
Jyoti Gupta, Agam Gupta, Sapna Gupta, and Three other members serve as directors at the Company.
- CIN/LLPIN
U24232JK2004PTC002393
- Company No.
002393
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
02 Apr 2004
- Date of AGM
30 Dec 2020
- Date of Balance Sheet
31 Mar 2020
- Listing Status
Unlisted
- ROC Code
Roc Jammu
Industry
Company Details
- Location
Jammu, Jammu & Kashmir, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Parenteral Pharma?
Board Members(6)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Agam Gupta  | Director | 05-Aug-2021 | Current |
| Jyoti Gupta | Director | 05-Aug-2021 | Current |
| Sapna Gupta | Director | 05-Aug-2021 | Current |
| Rozy Gupta | Director | 05-Aug-2021 | Current |
| Sahib Gupta | Director | 05-Aug-2021 | Current |
| Shanti Gupta | Director | 05-Aug-2021 | Current |
Financial Performance and Corporate Structure Insights of Parenteral Pharma.
Parenteral Pharma Private Limited, for the financial year ended 2020, experienced no change in revenue, with a 0% increase. The company also saw a substantial fall in profitability, with a 60323.58% decrease in profit. The company's net worth observed a substantial decline by a decrease of 716.03%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Parenteral Pharma?
In 2018, Parenteral Pharma had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Punjab National Bank Creation Date: 17 Sep 2005 | ₹2.00 Cr | Open |
Punjab National Bank Creation Date: 31 May 2005 | ₹1.25 M | Open |
How Many Employees Work at Parenteral Pharma?
Unlock and access historical data on people associated with Parenteral Pharma, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Parenteral Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Parenteral Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
